PL3873883T3 - Sposób syntezy - Google Patents
Sposób syntezyInfo
- Publication number
- PL3873883T3 PL3873883T3 PL20816375.8T PL20816375T PL3873883T3 PL 3873883 T3 PL3873883 T3 PL 3873883T3 PL 20816375 T PL20816375 T PL 20816375T PL 3873883 T3 PL3873883 T3 PL 3873883T3
- Authority
- PL
- Poland
- Prior art keywords
- synthesis
- Prior art date
Links
- 230000015572 biosynthetic process Effects 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 238000003786 synthesis reaction Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D209/16—Tryptamines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1916210.6A GB201916210D0 (en) | 2019-11-07 | 2019-11-07 | High purity tryptamines and methods of synthesis thereof |
| GBGB1917320.2A GB201917320D0 (en) | 2019-11-28 | 2019-11-28 | Novel compounds |
| GB2008303.6A GB2585978B (en) | 2019-06-03 | 2020-06-02 | Therapeutic compositions |
| PCT/EP2020/081503 WO2021089873A1 (en) | 2019-11-07 | 2020-11-09 | Method of synthesis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3873883T3 true PL3873883T3 (pl) | 2023-05-08 |
Family
ID=75849570
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL20816376.6T PL3844147T3 (pl) | 2019-11-07 | 2020-11-09 | Związki chemiczne |
| PL20816375.8T PL3873883T3 (pl) | 2019-11-07 | 2020-11-09 | Sposób syntezy |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL20816376.6T PL3844147T3 (pl) | 2019-11-07 | 2020-11-09 | Związki chemiczne |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US11643390B2 (pl) |
| EP (3) | EP4180037A1 (pl) |
| JP (3) | JP7422473B2 (pl) |
| KR (2) | KR20230142817A (pl) |
| CN (2) | CN114829340B (pl) |
| AU (2) | AU2020378647B2 (pl) |
| BR (1) | BR112022008919A2 (pl) |
| CA (2) | CA3160337C (pl) |
| DK (1) | DK3844147T3 (pl) |
| ES (2) | ES2940811T3 (pl) |
| HR (2) | HRP20230281T1 (pl) |
| HU (2) | HUE059403T2 (pl) |
| IL (2) | IL292753B2 (pl) |
| MX (1) | MX2022005399A (pl) |
| NZ (1) | NZ788543A (pl) |
| PL (2) | PL3844147T3 (pl) |
| PT (2) | PT3844147T (pl) |
| WO (2) | WO2021089873A1 (pl) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201907871D0 (en) | 2019-06-03 | 2019-07-17 | Small Pharma Ltd | Therapeutic compositions |
| HRP20230281T1 (hr) | 2019-11-07 | 2023-04-28 | Small Pharma Ltd | Postupak sinteze |
| JP2023513680A (ja) | 2020-02-04 | 2023-04-03 | マインドセット ファーマ インコーポレイテッド | 中枢神経系障害の治療のためのセロトニン作動性幻覚薬としてのシロシン誘導体 |
| US11332441B2 (en) * | 2020-03-23 | 2022-05-17 | Caamtech, Inc. | Crystalline N-methyl tryptamine derivatives |
| KR20230012501A (ko) | 2020-05-19 | 2023-01-26 | 사이빈 아이알엘 리미티드 | 중수소화된 트립타민 유도체 및 사용 방법 |
| WO2021116503A2 (en) * | 2020-06-02 | 2021-06-17 | Small Pharma Ltd | Deuterated compounds |
| US11773062B2 (en) | 2021-03-22 | 2023-10-03 | Small Pharma Ltd | Deuterated compounds |
| US20210378969A1 (en) | 2020-06-02 | 2021-12-09 | Small Pharma Ltd. | Therapeutic solid dosage forms |
| KR102589605B1 (ko) * | 2020-06-02 | 2023-10-13 | 스몰 파마 엘티디 | 중수소화 또는 부분 중수소화 n,n-디메틸트립타민 화합물을 포함하는 치료용 조성물 |
| KR20230024378A (ko) | 2020-06-12 | 2023-02-20 | 벡클리 싸이테크 리미티드 | 5-메톡시-n, n-디메틸트립타민의 벤조에이트 염을 포함하는 조성물 |
| US11406619B2 (en) | 2020-08-28 | 2022-08-09 | Small Pharma Ltd | Injectable formulations |
| US11660289B2 (en) | 2020-12-01 | 2023-05-30 | Small Pharma Ltd. | Deuterated or partially deuterated N,N-dimethyltryptamine compounds |
| IL310296A (en) * | 2021-07-22 | 2024-03-01 | Gh Res Ireland Limited | A method for the preparation of a tryptamine derivative |
| EP4122916A1 (en) * | 2021-07-22 | 2023-01-25 | GH Research Ireland Limited | Method for preparing an organic compound |
| US11697638B2 (en) | 2021-09-08 | 2023-07-11 | Small Pharma Ltd | 5-methoxy-N,N-dimethyltryptamine crystalline forms |
| EP4159192A1 (en) | 2021-09-30 | 2023-04-05 | Biomind Labs Inc | Dimethyltriptamine-based nasal spray for the personalised treatment of neurological and psychiatric disorders |
| WO2023089132A1 (en) | 2021-11-18 | 2023-05-25 | Small Pharma Ltd | Injectable and inhalable formulations |
| WO2023108174A1 (en) * | 2021-12-10 | 2023-06-15 | Terran Biosciences, Inc. | Analogs of 6-methoxy- n, n-dimethyltryptamine |
| WO2023147423A1 (en) * | 2022-01-28 | 2023-08-03 | Miralogx Llc | Anxiolytic compounds, pharmaceutical compositions, and methods of treating anxiety and other disorders |
| GB202212116D0 (en) | 2022-08-19 | 2022-10-05 | Beckley Psytech Ltd | Pharmaceutically acceptable salts and Compositions thereof |
| US20240101514A1 (en) * | 2022-08-19 | 2024-03-28 | Beckley Psytech Limited | Pharmaceutically acceptable salts and compositions thereof |
| WO2024079314A1 (en) | 2022-10-13 | 2024-04-18 | Cybin Uk Ltd | Method of administration of a parenteral formulation comprising a psychedelic agent |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4336378A (en) | 1980-04-10 | 1982-06-22 | Sandoz, Inc. | Isoxazolyl indolamines |
| WO1993000333A1 (en) * | 1991-06-21 | 1993-01-07 | Smithkline Beecham Plc | Tryptamine analogues, their synthesis and their use as 5-ht1-like or 5-ht2 receptor agonists |
| US6376531B1 (en) | 1998-11-13 | 2002-04-23 | Rupert Charles Bell | Method of treatment using deuterium compounds |
| CA2412905A1 (en) | 2000-06-16 | 2001-12-27 | Rtp Pharma Inc. | Improved injectable dispersions of propofol |
| WO2004085392A1 (en) | 2003-03-25 | 2004-10-07 | Faust Pharmaceuticals | Melatonin derivatives and their use for treating neurological dysfunctions |
| AU2007310949A1 (en) | 2006-10-19 | 2008-04-24 | Auspex Pharmaceuticals, Inc. | Substituted indoles |
| WO2008071455A1 (en) | 2006-12-15 | 2008-06-19 | Bayer Schering Pharma Aktiengesellschaft | Bicyclic acyltryptophanols |
| CZ302424B6 (cs) * | 2007-06-13 | 2011-05-11 | Zentiva, A. S. | Zpusob prípravy almotriptanu o vysoké cistote |
| AU2008283903B2 (en) * | 2007-08-06 | 2014-01-16 | Biotie Therapies, Inc | Methods for treating dependence |
| US20090076121A1 (en) | 2007-09-14 | 2009-03-19 | Protia, Llc | Deuterium-enriched sumatriptan |
| EP2209380A4 (en) | 2007-10-09 | 2011-09-14 | Mark T Hamann | METHOD OF USE OF COMPOSITIONS WITH ANTIDEPRESSIVE EFFICACY, MOOD EFFICACY AND OTHER NEUROLOGICAL EFFECTIVENESS AND COMPOSITIONS THEREOF |
| SG11201504709PA (en) * | 2013-03-14 | 2015-07-30 | Dart Neuroscience Llc | Substituted pyridine and pyrazine compounds as pde4 inhibitors |
| US10336703B2 (en) | 2015-05-12 | 2019-07-02 | Council Of Scientific And Industrial Research | Process for the synthesis of ivacaftor and related compounds |
| US20200030309A1 (en) * | 2016-09-29 | 2020-01-30 | The Regents Of The University Of California | Compounds for increasing neural plasticity |
| CA3052974A1 (en) | 2017-02-09 | 2018-08-16 | CaaMTech, LLC | Compositions and methods comprising a psilocybin derivative |
| WO2018195455A1 (en) | 2017-04-20 | 2018-10-25 | Eleusis Benefit Corporation, Pbc | Assessing and treating psychedelic-responsive subjects |
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| EP3713568A1 (en) * | 2017-10-26 | 2020-09-30 | Consejo Superior de Investigaciones Cientificas (CSIC) | Combination product for the treatment of neurological and/or psychiatric disorders |
| US11117870B2 (en) | 2017-11-01 | 2021-09-14 | Drexel University | Compounds, compositions, and methods for treating diseases |
| CN114555078A (zh) | 2019-02-22 | 2022-05-27 | Gh研究爱尔兰有限公司 | 用于治疗抑郁症的5-甲氧基-n,n-二甲基色胺(5-meo-dmt) |
| CN114423422A (zh) | 2019-02-22 | 2022-04-29 | Gh研究爱尔兰有限公司 | 用于治疗精神障碍的含有5-甲氧基-n,n-二甲基色胺(5-meo-dmt)的组合物 |
| AU2020229779A1 (en) | 2019-02-27 | 2021-09-09 | The Regents Of The University Of California | Azepino-indoles and other heterocycles for treating brain disorders |
| AU2020228289A1 (en) * | 2019-02-27 | 2021-09-09 | The Regents Of The University Of California | N-substituted indoles and other heterocycles for treating brain disorders |
| GB201907871D0 (en) | 2019-06-03 | 2019-07-17 | Small Pharma Ltd | Therapeutic compositions |
| HRP20230281T1 (hr) | 2019-11-07 | 2023-04-28 | Small Pharma Ltd | Postupak sinteze |
| CN111072492A (zh) * | 2019-11-29 | 2020-04-28 | 浙江工业大学 | 一种合成3,4-二氯-2-氨基-5-氟联苯的方法 |
| JP2023513680A (ja) | 2020-02-04 | 2023-04-03 | マインドセット ファーマ インコーポレイテッド | 中枢神経系障害の治療のためのセロトニン作動性幻覚薬としてのシロシン誘導体 |
| KR20230012501A (ko) | 2020-05-19 | 2023-01-26 | 사이빈 아이알엘 리미티드 | 중수소화된 트립타민 유도체 및 사용 방법 |
| WO2021234608A1 (en) | 2020-05-19 | 2021-11-25 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
| US20210378969A1 (en) | 2020-06-02 | 2021-12-09 | Small Pharma Ltd. | Therapeutic solid dosage forms |
| WO2021116503A2 (en) | 2020-06-02 | 2021-06-17 | Small Pharma Ltd | Deuterated compounds |
| US11773062B2 (en) | 2021-03-22 | 2023-10-03 | Small Pharma Ltd | Deuterated compounds |
| GB202008961D0 (en) | 2020-06-12 | 2020-07-29 | Beckley Psytech Ltd | Pharmaceutical composition |
| WO2022031566A1 (en) | 2020-08-05 | 2022-02-10 | Universitatsspital Basel | Intravenous dmt administration method for dmt-assisted psychotherapy |
| CN115701994B (zh) | 2020-08-28 | 2024-03-08 | 赛本英国有限公司 | 可注射制剂 |
| US20220062237A1 (en) | 2020-08-28 | 2022-03-03 | Small Pharma Ltd | Injectable formulation |
| US11406619B2 (en) | 2020-08-28 | 2022-08-09 | Small Pharma Ltd | Injectable formulations |
| KR20230079351A (ko) | 2020-10-02 | 2023-06-07 | 사이빈 아이알엘 리미티드 | 흡입에 의한 심리치료제(psychedelic) 약물의 전달을 위한 방법 및 이 방법을 수행하기 위한 시스템 |
| US11000534B1 (en) | 2020-10-08 | 2021-05-11 | Lennham Pharmaceuticals, Inc. | Deuterated derivatives of psilocybin and uses thereof |
-
2020
- 2020-11-09 HR HRP20230281TT patent/HRP20230281T1/hr unknown
- 2020-11-09 PT PT208163766T patent/PT3844147T/pt unknown
- 2020-11-09 IL IL292753A patent/IL292753B2/en unknown
- 2020-11-09 EP EP22214748.0A patent/EP4180037A1/en active Pending
- 2020-11-09 EP EP20816376.6A patent/EP3844147B1/en active Active
- 2020-11-09 CA CA3160337A patent/CA3160337C/en active Active
- 2020-11-09 PL PL20816376.6T patent/PL3844147T3/pl unknown
- 2020-11-09 HU HUE20816376A patent/HUE059403T2/hu unknown
- 2020-11-09 WO PCT/EP2020/081503 patent/WO2021089873A1/en unknown
- 2020-11-09 CN CN202080087091.0A patent/CN114829340B/zh active Active
- 2020-11-09 EP EP20816375.8A patent/EP3873883B1/en active Active
- 2020-11-09 DK DK20816376.6T patent/DK3844147T3/da active
- 2020-11-09 CN CN202080087092.5A patent/CN114829341B/zh active Active
- 2020-11-09 PL PL20816375.8T patent/PL3873883T3/pl unknown
- 2020-11-09 ES ES20816375T patent/ES2940811T3/es active Active
- 2020-11-09 JP JP2022526073A patent/JP7422473B2/ja active Active
- 2020-11-09 PT PT208163758T patent/PT3873883T/pt unknown
- 2020-11-09 WO PCT/EP2020/081502 patent/WO2021089872A1/en active Application Filing
- 2020-11-09 BR BR112022008919A patent/BR112022008919A2/pt not_active Application Discontinuation
- 2020-11-09 HR HRP20220797TT patent/HRP20220797T1/hr unknown
- 2020-11-09 NZ NZ788543A patent/NZ788543A/en unknown
- 2020-11-09 HU HUE20816375A patent/HUE061482T2/hu unknown
- 2020-11-09 ES ES20816376T patent/ES2920681T3/es active Active
- 2020-11-09 JP JP2022526074A patent/JP7423131B2/ja active Active
- 2020-11-09 AU AU2020378647A patent/AU2020378647B2/en active Active
- 2020-11-09 MX MX2022005399A patent/MX2022005399A/es unknown
- 2020-11-09 KR KR1020237033500A patent/KR20230142817A/ko not_active Application Discontinuation
- 2020-11-09 CA CA3160334A patent/CA3160334C/en active Active
- 2020-11-09 AU AU2020381103A patent/AU2020381103B2/en active Active
- 2020-11-09 KR KR1020227018623A patent/KR20220082092A/ko not_active IP Right Cessation
-
2021
- 2021-08-26 US US17/412,828 patent/US11643390B2/en active Active
-
2022
- 2022-05-03 IL IL292754A patent/IL292754A/en unknown
- 2022-05-06 US US17/662,261 patent/US11578039B2/en active Active
-
2023
- 2023-01-10 US US18/152,465 patent/US20230167056A1/en active Pending
- 2023-03-31 US US18/193,866 patent/US20230250059A1/en active Pending
- 2023-11-30 JP JP2023202672A patent/JP2024028798A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL292754A (en) | method of synthesis | |
| IL271938A (en) | A method for making synthesis gas | |
| IL271939A (en) | A method for making synthesis gas | |
| IL271941A (en) | A method for making synthesis gas | |
| EP3712130A4 (en) | METHOD OF SYNTHESIS OF ROXADUSTATE AND INTERMEDIATE COMPOUNDS THEREOF | |
| ZA201908158B (en) | Novel method for synthesizing amanitins | |
| EP3611171A4 (en) | METHOD OF SYNTHESIS OF ELIGLUSTAT AND INTERMEDIATE COMPOUNDS THEREOF | |
| GB201801768D0 (en) | Synthesis method | |
| GB201701396D0 (en) | Novel alternating-phase synthesis method | |
| GB201804594D0 (en) | Bonegraft substituteand method of manufacture | |
| IL292210A (en) | An efficient process for the synthesis of 2-amino-5-chloro-n,3-dimethylbenzamide | |
| ZA202101837B (en) | Method for the preparation of synthesis gas | |
| GB201802839D0 (en) | Method of manufacture | |
| IL291221A (en) | Methods for the synthesis of wolbenzine | |
| GB201903056D0 (en) | Method of oligonucleotide synthesis | |
| PL3755681T3 (pl) | Sposób wytwarzania 4-boronofenyloalaniny | |
| GB201903055D0 (en) | Method of oligonucleaotide synthesis | |
| PL3498665T3 (pl) | Sposób otrzymywania gazu syntezowego | |
| PT3759082T (pt) | Processo para a síntese de 6-clorometiluracilo | |
| EP3792296C0 (en) | PROCESS FOR THE SYNTHESIS OF POLYETHERS | |
| GB201804905D0 (en) | Cataltic synthesis of biarylic compounds | |
| GB201917499D0 (en) | Methods of synthesis | |
| GB201809404D0 (en) | Method of synthesis | |
| GB201807468D0 (en) | Methods of synthesis | |
| GB202017799D0 (en) | Method of synthesis |